3-fluorosuberanilohydroxamic acid | 149648-07-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-fluorosuberanilohydroxamic acid
• 英文别名: N-(3-fluorophenyl)-N'-hydroxyoctanediamide
• CAS: 149648-07-7
• 化学式: C₁₄H₁₉FN₂O₃
• 分子量: 282.315
• InChiKey: SWNKFBHPQVPRNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  Methyl 8-(3-fluoroanilino)-8-oxooctanoate 在 羟胺 、 potassium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 3-fluorosuberanilohydroxamic acid
  参考文献：
  名称：

  Precursor-Directed Biosynthesis of Aminofulvenes: New Chalanilines from Endophytic Fungus Chalara sp.

  摘要：

  植物内生真菌 Chalara sp. 能够将表观遗传修饰剂 vorinostat 生物转化为形成独特的含苯胺的聚酮类化合物，被命名为 chalanilines。在这里，我们试图通过改变前体 vorinostat 中的苯胺基团来扩展 chalaniline A 类分子的化学多样性。总共，通过两步合成制备了二十三种不同的 vorinostat 类似物，其中十九种被真菌转化为聚酮类化合物。选择产量最高的底物进行大规模前体导向生物合成，分离、纯化并结构表征了五种新化合物，包括两种氟代 chalanilines。结构阐明依赖于一维和二维核磁共振技术，并得到低分辨率和高分辨率质谱的支持。所有化合物均进行了生物活性测试，但在抗微生物或细胞存活率测定中均不活跃。含氨基富烯的天然产物很少见，而这种高产率的前体导向过程允许对这类化合物进行多样化。

  DOI：

  10.3390/molecules26154418

文献信息

• Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
  申请人：Emory University

  公开号：EP2364702A2

  公开（公告）日：2011-09-14

  A composition is provided which comprises one or more Kinase inhibitors for use for preventing or treating a pathogenic infection caused by a broad array of pathogens in a patient in need thereof.

  本发明提供了一种组合物，其中包含一种或多种激酶抑制剂，用于预防或治疗由多种病原体引起的病原体感染。
• Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof
  申请人：Emory University

  公开号：EP2471529A2

  公开（公告）日：2012-07-04

  A composition is provided which comprises one or more Kinase inhibitors for use for preventing or treating a pathogenic infection caused by a broad array of pathogens in a patient in need thereof.

  本发明提供了一种组合物，其中包含一种或多种激酶抑制剂，用于预防或治疗由多种病原体引起的病原体感染。
• Modified Cap Group Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitor Derivatives Reveal Improved Selective Antileukemic Activity
  作者：Chanaz Salmi-Smail、Aurélie Fabre、Franck Dequiedt、Audrey Restouin、Rémy Castellano、Slaveia Garbit、Philippe Roche、Xavier Morelli、Jean Michel Brunel、Yves Collette

  DOI：10.1021/jm901358y

  日期：2010.4.22

  A series of SAHA cap derivatives was designed and prepared in good-to-excellent yields that varied from 49% to 95%. These derivatives were evaluated for their antiproliferative activity in several human cancer cell lines. Antiproliferative activity was observed for concentrations varying from 0.12 to > 100 mu M, and a molecular modeling approach of selected SAHA derivatives, based on available structural information of human HDAC8 in complex with SAHA, was performed. Strikingly, two compounds displayed up to 10-fold improved antileukemic activity with respect to SAHA; however, these compounds displayed antiproliferative activity similar to SAHA when assayed against solid tumor-derived cell lines. A 10-fold improvement in the leukemic vs peripheral blood mononuclear cell therapeutic ratio, with no evident in vivo toxicity toward blood cells, was also observed. The herein-described compounds and method of synthesis will provide invaluable tools to investigate the molecular mechanism responsible for the reported selectively improved antileukemic activity.
• KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF
  申请人：Kalman Daniel

  公开号：US20120302565A1

  公开（公告）日：2012-11-29

  The present invention provides compositions and methods of use thereof to prevent and/or treat pathogenic infection. In particular, the present invention provides the use of kinase inhibitors to inhibit kinases that involve in pathogen-host cell interactions that are associated with or cause pathogenic infections, therefore, to effectively prevent and/or treat pathogenic infections with far less likely to engender resistance as compared to conventional antibiotics and anti-viral drugs. The present invention further provides the use of kinase inhibitors for the treatment of acute pathogenic infections for a short period of time to avoid toxicities that may caused by long term use of these kinase inhibitors.
• COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS
  申请人：Larsson Pia

  公开号：US20140051716A1

  公开（公告）日：2014-02-20

  There is provided a compound which is a histone deacetylase (HDAC) inhibitor, or a pharmaceutically acceptable ester, amide, solvate or salt thereof, for use in: (I) treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation; and/or (II) potentiating the degradation of fibrin deposits and preventing such deposits associated with pathological conditions or which may lead to such conditions, wherein the HDAC inhibitor, and the dose thereof, is as described in the description. There is also provided valproic acid, or a pharmaceutically acceptable salt thereof, for use in improving or normalizing endogenous fibrinolysis impaired by local or systemic inflammation.